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Profilin 1 (PFN1) is a regulator of the microfilament system and is involved in various signaling pathways. It interacts with
many cytoplasmic and nuclear ligands. The importance of PFN1 for human tissue differentiation has been demonstrated
by the findings that human cancer cells, expressing conspicuously low PFN1 levels, adopt a nontumorigenic phenotype
upon raising their PFN1 level. In the present study, we characterize the ligand binding site crucial for profilin’s tumor
suppressor activity. Starting with CAL51, a human breast cancer cell line highly tumorigenic in nude mice, we established
stable clones that express PFN1 mutants differentially defective in ligand binding. Clones expressing PFN1 mutants with
reduced binding to either poly-proline-stretch ligands or phosphatidyl-inositol-4,5-bisphosphate, but with a functional
actin binding site, were normal in growth, adhesion, and anchorage dependence, with only a weak tendency to elicit
tumors in nude mice, similar to controls expressing wild-type PFN1. In contrast, clones expressing a mutant with severely
reduced capacity to bind actin still behaved like the parental CAL51 and were highly tumorigenic. We conclude that the
actin binding site on profilin is instrumental for normal differentiation of human epithelia and the tumor suppressor
function of PFN1.
INTRODUCTION
Profilins are small (14- to 17-kDa) proteins found in verte-
brates and invertebrates, protozoa, fungi, plants, and certain
viruses. Most eukaryotes contain more than one profilin
gene, and splicing may generate further isoforms. The im-
portance of profilins for normal cell proliferation and differ-
entiation has been documented in genetic studies, showing
that profilin gene disruption leads to grossly impaired
growth, motility, and cytokinesis in single cells (Haugwitz et
al., 1994; Magdolen et al., 1988) and embryonic lethality in
multicellular organisms such as insects (Verheyen and
Cooley, 1994) and mice (Witke et al., 1993, 2001). A minimum
level of profilin was found critical for differentiation of hu-
man epithelial cells, whereas a profilin level below this mark
correlates with the tumorigenic state of breast cancer cells
and tissue, classifying profilin as a tumor suppressor protein
(Janke et al., 2000).
Immunofluorescence and fluorescence microscopy with
green fluorescent protein (GFP)-profilin–transfected cells re-
vealed profilin as a constituent of highly dynamic microfila-
ment structures associated with cellular membranes, such as
the cortical web of lamellipodia (Buss et al., 1992), nascent
focal adhesions (Mayboroda et al., 1997), and surface ruffles
(Wittenmayer et al., 2000), and also as a component of intra-
cellular vesicles (Dong et al., 2000). Furthermore, profilin
was localized in intranuclear bodies, such as speckles, Cajal
bodies, and gems (Giesemann et al., 1999; Skare et al., 2003).
Biochemical analysis showed that profilins interact with a
plethora of ligands, in particular with actin (Carlsson et al.,
1977), the actin-related protein (Arp)2 (Machesky, 1997),
gephyrin (Giesemann et al., 2003), the acidic phospholipid
phosphatidyl-inositol-4,5-bisphosphate (PIP2; Lassing and
Lindberg, 1985; Sohn et al., 1995; Lambrechts et al., 2002;
Skare and Karlsson, 2002), and a large catalog of proteins
comprising a poly-proline stretch. Due to the functional
diversity of the latter, there is no unifying hypothesis on the
biological meaning of such interactions. In contrast, the con-
sequences of profilin’s interaction with actin and PIP2 in
mammalian cells are much better understood (cf. Lassing
and Lindberg, 1985; Goldschmidt-Clermont et al., 1990;
Aderem, 1992; Goldschmidt-Clermont et al., 1992; Pantaloni
and Carlier, 1993; Perelroizen et al., 1996; and for review,
Schlu¨ter et al., 1997). Under physiological conditions, profi-
lins are potent regulators of actin filament dynamics, by
promoting the exchange of ADP to ATP on actin and by the
affinity of profilin–actin complexes for actin filament ends.
Regional actin polymerization may be ensured by high local
concentrations of profilin–actin complexes, bound to the
poly-proline-stretch proteins vasodilator stimulated phos-
phoprotein (VASP; Reinhard et al., 1995), p140mDia (Wa-
tanabe et al., 1997; Krebs et al., 2001), or neuronal Wiscott-
Aldrich-Syndrome protein (Suetsugu et al., 1998), which are
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actin- and plasma membrane-associated proteins (Holt and
Koffer, 2001), and by profilin’s binding to PIP2. Because a
major PIP2 binding site on profilin overlaps with the actin
binding site, fluctuations in the PIP2 level, caused by exter-
nal stimuli, may cause profilin to shuttle between a mem-
brane-bound to an actin-bound form, performing as a potent
mediator in the signal cascade leading from external signals
to microfilaments (Machesky and Pollard, 1993).
Although this concept of profilin’s function is attractive,
many details remain unclear. In particular, there is no infor-
mation on the consequence of profilin’s binding to specific
ligands for cell proliferation and differentiation in higher
eukaryotes. In this context, we challenged the role of three
major binding sites on profilin, for actin, PIP2, and the
poly-proline-stretch, in human epithelial differentiation. Pre-
viously, we had reported that the cell line CAL51 and other
human breast cancer cell lines displayed a conspicuously
low level of profilin. When the profilin level was raised in
CAL51, either by transfer of the chromosomal fragment
harboring the profilin 1 gene, or by transfecting the cells
with cDNA coding for profilin 1, the transformed phenotype
and tumorigenicity of CAL51 cells was markedly reduced
(Theile et al., 1995; Janke et al., 2000).
We now transfected CAL51 cells with profilin 1 mutants
defective in binding to actin, poly-proline, or PIP2 and gen-
erated cell clones stably expressing the mutant profilins.
These cells were analyzed with respect to tumor-related
phenomena, such as independence of substrate adhesion,
inability to differentiate, and the generation of tumors in
nude mice. Our results indicate that a minimal level of a
functional actin binding site on profilin is critical and indis-
pensable for suppression of tumorigenicity in human epi-
thelia.
MATERIALS AND METHODS
Preparation of Expression Constructs
The mutants of human profilin 1 (PFN1), PFN1/Y59A, PFN1/H133S, and
PFN1/R88L were generated by site-directed mutagenesis (QuikChange site-
directed mutagenesis kit; Stratagene, La Jolla, CA). For the expression in
human cells or bacteria, mutated and wild-type PFN1 cDNAs were cloned
either into modified pcDNA3 or pET21c vectors (Novagen, Madison, WI),
respectively. Both vectors harbored the BiPro-tag sequence (Ru¨diger et al.,
1997).
Expression, Purification, and Characterization of
Recombinant Proteins
Wild-type, unmodified, and BiPro-tagged human profilin 1 was expressed in
Escherichia coli BL21 (DE3) essentially as described previously (Wittenmayer et
al., 2000). All mutants were expressed in and purified from E. coli as described
previously (Schlu¨ter et al., 1998), and purified from bacterial lysates by affinity
chromatography on poly-(l-proline)-columns (Tanaka and Shibata, 1985;
Lindberg et al., 1988; Wittenmayer et al., 2000). The mutant PFN1/H133S is not
retained by such columns but trails in a separate peak. Collected fractions
were analyzed by SDS-PAGE, and purity of the preparation was 90%, as
judged from Coomassie-stained gels. Protein concentration was quantified by
the Bradford assay, using bovine serum albumin (BSA) as a standard. Native
configuration of all proteins was determined by CD spectra. Their respective
defect in ligand binding was characterized with untagged proteins in bio-
chemical assays. The affinity for actin was determined with pyrene-labeled
skeletal muscle actin at steady state (Schlu¨ter et al., 1998), by using gelsolin-
capped actin filaments, as described previously (Bjorkegren-Sjogren et al.,
1997; Lambrechts et al., 2002). Pig plasma gelsolin was a generous gift of Dr.
H. Hinssen (University of Bielefeld, Bielefeld, Germany) and, additionally,
was purchased from Sigma Chemie (Taufkirchen, Germany). Retardation on
poly-proline-Sepharose columns was used as a criterion for binding to poly-
proline-stretch ligands. Binding to PIP2 was monitored with two different
assays. Dot overlay assays were performed with 0.02–1 g of PIP2 micelles
(prepared as in Hu¨ttelmaier et al., 1998), spotted onto polyvinylidene difluo-
ride membranes (Roth, Karlsruhe, Germany), and sequentially incubated
with 3% BSA for 1 h, 30 M profilin, and 0.3% milk powder in phosphate-
buffered saline. Bound profilin was detected with the monoclonal anti-profilin
as described for immunoblotting. Microfiltration assays were performed es-
sentially as described previously (Lambrechts et al., 1997; Skare and Karlsson,
2002). Increasing amounts of freshly prepared PIP2 micelles were incubated
with 0.5 nmol of profilin. Free and PIP2-bound profilins were separated by
centrifugation through PLTK filters (Millipore, Eschborn, Germany). The
flow-through, containing unbound profilin, was either concentrated, sub-
jected to SDS-PAGE, and Coomassie Blue staining, or used directly in SDS-
PAGE and immunoblotting with anti-profilin. The dot overlay and both
variants of the microfiltration assays gave identical results. The data for
ligand binding obtained for all recombinant proteins are shown in Table 1.
Cell Culture, Transfection, and Isolation of Stable Clones
The mammary epithelial MCF-10A cell line was grown in DMEM/Ham’s F12
(1:1) medium supplemented with 20 ng/ml epidermal growth factor, 0.01
mg/ml insulin, 500 ng/ml hydrocortisone, and 5% horse serum. The cell line
CAL51 and its nontumorigenic microcell hybrid CAL/17-5 (Theile et al., 1995)
were grown in DMEM supplemented with 10% fetal calf serum. CAL51 cells
were transfected with plasmid DNAs (pcDNA3, pcDNA-PFN1, pcDNA-
PFN1/Y59A, pcDNA-PFN1/H133S, and pcDNA-PFN1/R88L) by using Fu-
GENE 6 transfection reagent (Roche Diagnostics, Mannheim, Germany) ac-
cording to the manufacturer’s instructions. Selection with 800 g/ml G418
started 48 h after transfection and G418-resistant clones were isolated 2–3 wk
later.
Preparation of Cell Lysates and Immunoblotting
Cells were harvested and resuspended in ice-cold lysis buffer (50 mM Tris/
HCl, pH 7.4, 10 mM NaCl, 5 mM EDTA, 0.3% Triton X-100 containing a
protease inhibitor mix [10 M leupeptin, 20 U/ml aprotinin, 1 M pepstatin
A, and 100 M pefabloc SC]). After 15-min incubation on ice, cell fragments
were homogenized by passing the suspension through a syringe. Analogous
procedures were used to obtain total protein extracts from tumor tissue (see
below). The resulting suspension was centrifuged for 5 min at 13,000 rpm, and
protein concentration of the supernatant was determined by Bradford assay,
by using BSA as a standard. Equal amounts of proteins (in the range of 5–15
g) were separated by SDS-PAGE on tricine-containing gels (Scha¨gger and
Jagow, 1987; Wittenmayer et al., 2000) and transferred onto nitrocellulose
membrane. Membranes were blocked with 5% nonfat milk in phosphate-
buffered saline. Endogenous and transfected BiPro-tagged profilin, and en-
dogenous tubulin were monitored with the following antibodies: monoclonal
anti-profilin (Mayboroda et al., 1997), monoclonal antibody against the BiPro
tag (Ru¨diger et al., 1997) or monoclonal anti-tubulin (Sigma Chemie), respec-
tively. Immunoreactive bands were detected using a horseradish peroxidase-
conjugated goat anti-mouse IgG (Sigma Chemie) for a second antibody and
by enhanced chemiluminescence (Amersham Biosciences, Freiburg, Ger-
many). The intensity of the signals was determined by densitometry (EASY-
Table 1. Ligand binding capacity of the point mutants of human profilin 1 used in this study
Protein
Binding to actin:
Kd valuesa
Binding to poly-proline: binding
to poly-proline–Sepharose column
Binding to PIP2 in dot overlay
and microfiltration assays
Wild-type PFN1 0.71  106 M 6–8 M urea needed for elution 100%
PFN1/Y59A 2.11 105 M 6–8 M urea needed for elution Like wild-type PFN1
PFN1/H133S 1.09 106 M No binding Like wild-type PFN1
PFN1/R88L 2.03 106 M 6–8 M urea needed for elution Less than 30% of wild-type value
Data were obtained with recombinant proteins purified and analysed as described in MATERIALS AND METHODS.
a Determined at steady state with gelsolin-capped filaments. The critical concentration of the actin used was 0.87  106 M.
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win; Herolab, Wiesloch, Germany). For quantitative analysis, standard curves
were obtained with recombinant profilin 1 (5–50 ng) and BiPro-tagged pro-
filin 1 (5–30 ng), respectively. The levels of profilin expression were deter-
mined for at least five independent experiments and compared by variance
analysis (Student-Newman-Keuls; p  0.05), by using Statview 5.0 (SAS
Institute, Cary, NC).
Growth Assays
Colony-forming ability in soft agar of the various cell lines was analyzed
essentially as described previously (Theile et al., 1995), seeding 2.5  104 cells
in 60-mm dishes. After 3 wk at 37°C and in a humidified atmosphere con-
taining 10% CO2, the numbers of colonies were counted. Three independent
experiments were performed, and standard deviations were determined.
Growth dependence on adhesion to extracellular matrix was investigated by
seeding 5  104 cells per well on top of a layer of matrigel (BD Biosciences,
Palo Alto, CA). Cells were incubated at 37°C in a humidified atmosphere
containing 10% CO2. After 48 h to 6 d, colonies were photographed using an
Axiovert 100 microscope (Carl Zeiss, Oberkochen, Germany).
Analysis of Cell Spreading
Spreading of CAL51, PFN1-, PFN1/Y59A-, PFN1/H133S-, PFN1/R88L-trans-
fected CAL51 clones, and MCF-10A cells was monitored after seeding them
onto glass coverslips, essentially as described previously (Janke et al., 2000).
At 30 min after seeding, cells were fixed with 4% formaldehyde for 15 min,
permeabilized with 0.2% Triton X-100, and stained with phalloidin-fluores-
cein isothiocyanate (Sigma Chemie). The cells were divided into two groups
according to gross differences in surface area and microfilament organization:
flat cells already well spread, with well developed microfilament bundles
(group 1) and small, compact cells that displayed most of their actin filaments
at their periphery (group 2). Per coverslip, 500 cells were counted in three
independent experiments and analyzed by variance analysis (Student-New-
man-Keuls; p  0.05), by using Statview 5.0.
Tumorigenicity Test, Histopathology, and Preparation of
Tumor Tissue Extracts
From each clone, 106 or 105 cells, respectively, were suspended in 0.1 ml of
serum-free medium and injected subcutaneously into 5- to 6-wk-old female
immunodeficient nude mice (BlnA:NMRI-nu/nu). Appearance and size of
tumors were examined weekly. After 11 wk, the mice were killed, and
subcutaneous tumors were removed and measured. Then, 5-m sections were
obtained from formalin-fixed, paraffin-embedded tumor tissue blocks, stained
with hematoxylin/eosin, and examined in a light microscope (BX-50; Olym-
pus, Tokyo, Japan). To quantify the amount of profilin expressed in the tumor
tissue, aliquots were homogenized in liquid nitrogen and lysis buffer (20 mM
Tris/HCl, pH 8.0, 100 mM NaCl, 500 mM EDTA, 50 mM dithioerythritol, and
protease inhibitor mix). The suspension was sheared several times through a
26G gauge needle. Cell debris was removed by centrifugation at 13,000  g at
4°C for 15 min, and the protein concentration in the supernatant was deter-
mined by Bradford assay.
RESULTS
Point Mutations in Profilin1 Yield Proteins Defective in
Binding to Specific Ligands
To reduce specific ligand binding in human PFN1, we used
three point mutations, created by site-directed mutagenesis.
Two of these, PFN1/H133S and PFN1/R88L, had been pre-
viously designed to create mutants specifically deficient in
polyproline- or PIP2 binding, respectively (Bjorkegren et al.,
1993; Sohn et al., 1995). The third one, PFN1/Y59A, was
designed according to our previous study on bovine profilin
1, where an analogous mutation (F59A) had displayed a
greatly reduced actin binding (Schlu¨ter et al., 1998). The
resulting recombinant proteins were expressed in and puri-
fied from E. coli and tested for the respective defect in
biochemical assays. As can be seen from Table 1, all three
mutants showed the expected defect in binding the respec-
tive ligand: compared with wild-type PFN1, actin binding of
the PFN1/Y59A mutant was decreased by a factor of 30,
PIP2 binding of PFN1/R88L was less than one-third of the
wild-type value, and PFN1/H133S was not retained on
poly-proline columns. In contrast, binding to the other li-
gands was not or only moderately affected: PIP2 binding of
PFN1/Y59A and PFN1/H133S, and poly-proline binding of
PFN1/Y59A and PFN1/R88L was as good as seen for wild-
type PFN1. PFN1/R88L, however, the mutant substantially
defective in PIP2 binding, displayed also a slightly reduced
binding to actin.
Expression of Mutated Profilins in CAL51 Cells Yields
Clones with Moderate Overall Profilin Levels
CAL51 cells were transfected with vectors coding for PFN1
wild-type or PFN1 point mutations equipped with the BiPro
tag (Ru¨diger et al., 1997). Stable clones were selected and the
level of endogenous and transfected profilins was deter-
mined in quantitative immunoblots. Figure 1 shows the
results obtained for the various clones. Tubulin was moni-
tored to ensure equal loading of total proteins (Figure 1A),
and the amount of the transfected profilin was determined
from standard curves obtained with the tag antibody (Figure
1B), whereas the endogenous profilin was monitored in the
same manner with a monoclonal anti-profilin reacting with
human profilin 1 (Mayboroda et al., 1997). Figure 1C shows
the results obtained for the various clones. The epithelial
control cell line MCF-10A contained 4.5 ng profilin/g
protein, and a similar value was measured for the nontu-
morigenic CAL/17-5 microcell hybrid that had been ob-
tained after chromosomal transfer (Theile et al., 1995). The
parental tumor cell line CAL51 and a stable clone mock-
transfected with the empty vector expressed 3 ng profi-
lin/g protein. Similar levels were found for a number of
other human cancer cell lines (Janke et al., 2000). Transfect-
ing CAL51 with wild-type PFN1 or the three different PFN1
point mutants resulted in clones, expressing the exogenous
protein to varying degrees, between 30 and 50% of the
endogenous profilin. The difference in total profilin content
between CAL51 and mock-transfected cells on one hand and
the lines expressing exogenous profilin was statistically sig-
nificant.
PFN1/Y59A Expression Cannot Restore Anchorage
Dependence in CAL51 Cells
To determine which of the profilin mutants might interfere
with the tumorigenic state of CAL51, we first analyzed
anchorage independence of growth, a criterion frequently
used in the characterization of tumorigenic cells. Previously,
we had already shown that CAL51 cells grow well in soft
agar, whereas the expression of wild-type profilin 1 induced
by either cDNA transfection or chromosomal transfer leads
to loss of this ability (Janke et al., 2000). We now tested the
various clones stably expressing the respective profilin mu-
tants in this assay. Figure 2 shows that a defect in poly-
proline binding or in phospholipid binding does not allow
for growth in soft agar. Expression of these profilin mutants
suppresses this ability drastically, similar to the situation
found for clones synthesizing wild-type profilin. In contrast,
expression of the profilin mutant with a grossly defective
actin binding site (PFN1/Y59A) does not interfere with an-
chorage-independent growth (Figure 2).
PFN1/Y59A Expression Cannot Normalize Cell Spreading
and Microfilament Organization
CAL51, as many tumor lines, displays a delay in adherence
and spreading on solid substrates, combined with a not very
well organized microfilament system. Elevation of the pro-
filin level in CAL51, however, normalizes these phenomena:
CAL51 cells expressing exogenous wild-type profilin 1 ad-
here and spread faster and show a microfilament organiza-
tion more reminiscent of epithelial cells (Janke et al., 2000).
To elucidate the importance of the profilin-actin binding site
for cell spreading and adherence, we analyzed the various
clones shortly after seeding them onto glass. Figure 3 dem-
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onstrates the data obtained for cells fixed and stained with
rhodamine-phalloidin at 30 min after seeding. Based on their
morphology and microfilament organization, the cells could
be classified into two groups: well spread; flat cells with
distinct microfilament bundles and focal contacts; and
round, compact cells that had not spread within 30–60 min
after seeding (Figure 3A). Figure 3B shows that CAL51 cells
expressing wild-type profilin 1 or any of the mutant profilins
defective in poly-proline or phospholipid binding displayed
a high proportion of cells that were well spread at 30 min
after seeding, similar to cells of the normal epithelial line
MCF-10A. The cells synthesizing PFN1/R88L or PFN1/
H133S were even slightly better in their capacity to adhere
and spread shortly after seeding. In contrast, CAL51 paren-
tal and CAL51 mock-transfected cells and the clones ex-
pressing the profilin mutant defective in actin binding were
delayed in adherence and spreading. The observed differ-
ences between the CAL51 cells, the mock-transfected line
and all three lines expressing PFN1/Y59A on one hand and
the MCF-10A epithelial line, the wild-type PFN1 expressing
CAL51 line and the five lines either expressing PFN1/R88L
or PFN1/H133S on the other hand were statistically signif-
icant, emphasizing the importance of an intact actin binding
site on profilin for normal epithelioid adherence and micro-
filament organization.
PFN1/Y59A Expression Does Not Permit an Epithelioid
Phenotype on Matrigel
We next tested the various cell clones under experimental
conditions that were more similar to the in vivo situation.
When embedded in or seeded onto Matrigel, normal epithe-
lial cells have the capacity to organize into tissue-like struc-
tures and develop tubular elements reminiscent of epithelial
ducts, whereas malignant breast tumor cells have lost this
ability and grow in compact, three-dimensional lumps (Pe-
tersen et al., 1992). This difference is also observed for MCF-
10A normal epithelial cells and CAL51, and expression of
Figure 1. Expression of endogenous and transfected profilins in
derivatives of CAL51. (A) Example of immunoblots of extracts
obtained from CAL51 and the following stable clones: one clone
transfected with the empty vector (control), one clone transfected
with wild-type profilin 1 (PFN1), three clones transfected with the
profilin mutant defective in actin binding (PFN1/Y59A), two clones
transfected with the profilin mutant defective in PIP2 binding
(PFN1/R88L), and two clones transfected with the profilin mutant
defective in polyproline-binding (PFN1/H133S). All transfected
proteins were equipped with the BiPro tag (see MATERIALS AND
METHODS). The blot was reacted with monoclonal antibodies
against the BiPro tag, against endogenous profilin, and against
tubulin, respectively, to confirm equal loading of total protein. (B)
Standard curve obtained with purified BiPro-tagged profilin, to
demonstrate that the quantitative data shown in C were obtained
within the linear range of anti-BiPro reactivity. (C) Quantitation of
the amounts of endogenous and transfected, BiPro-tagged profilin
obtained from immunoblots as shown in A. The bars reflect values
and SEs obtained from five to 10 independent experiments, com-
pared by variance analysis (see MATERIALS AND METHODS).
Values obtained for the CAL/17-5 microcell hybrid and for the
MCF-10A normal epithelial line are also shown (left). Note that in
all transfected lines the total amount of profilin does not exceed the
profilin level of the nontumorigenic lines CAL/17-5 and MCF-10A.
Figure 2. Growth of CAL51 and derivatives in soft agar. CAL51
cells and the derivative clones indicated were plated in soft agar as
described in MATERIALS AND METHODS and examined for col-
ony formation after 3 wk. For explanation of different lines, see
Figure 1. CAL51 cells and mock-transfected cells (control) estab-
lished numerous colonies, whereas a line supplemented with wild-
type profilin (PFN1-1) did not grow under these conditions. Note
that among the lines expressing mutant profilins, PFN1/R88L and
PFN1/H133S are reduced in colony growth, similar to the PFN1
clone, whereas PFN1/Y59A still retains the ability to grow in soft
agar. The SD from the mean is given for three independent exper-
iments.
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wild-type profilin in CAL51 shifts CAL51 toward a more
epithelial organization (Janke et al., 2000). To determine the
ability of the profilin mutants in this respect, we seeded
aliquots of the relevant cell clones onto matrigel and exam-
ined them over a period of 6 d. Representative images of the
results seen are shown in Figure 4. The CAL51 clones ex-
pressing profilin mutants were again seen to fall into two
classes: at 6 d after seeding, clones synthesizing profilins
defective in either poly-proline or phospholipid binding had
formed flat, epitheloid sheets, connected by tubular ele-
ments. These were very similar to structures obtained with
the normal epithelial line MCF-10A under analogous condi-
tions (Janke et al., 2000). In contrast, the clones expressing
profilin defective in actin binding were unable to show such
tissue-like organization but grew in small compact foci, like
the parental CAL51 line (Figure 4).
PFN1/Y59A Expression Cannot Prevent Tumor Growth in
Nude Mice
Finally, we challenged the importance of an intact actin
binding site on profilin for suppression of tumorigenicity in
nude mice. Our previous work had shown that elevation of
the profilin level in CAL51 cells by transfer of wild-type
profilin correlates with tumor suppression (Janke et al.,
2000). Figure 5 summarizes the results obtained for the
different cell lines, expressing profilin wild type or the cor-
responding mutants. Figure 5A compiles the data obtained
in relation to numbers of injected cells, injected animals, and
for tumor growth. Figure 5B demonstrates the kinetics of
tumor development. CAL51 parental and mock-transfected
cells elicited rapidly growing tumors after subcutaneous
injection of either 105 or 106 cells, and CAL51 cells express-
ing the mutant PFN1/Y59A were also highly tumorigenic,
yielding fast-growing tumors in all mice subcutaneously
injected with either 105 or 106 cells. In contrast, tumorige-
nicity was greatly reduced in animals injected with cells
expressing the profilin mutant primarily defective in poly-
proline binding. PFN1/H133S-containing cells elicited only
slow-growing tumors when injected at a high cell number
(106), and no tumors in animals injected with a 10-fold lower
dosis, comparable with that of CAL51 expressing wild-type
profilin (CAL/P-25 in Figure 5A). An intermediate capacity
in tumorigenesis was seen in the PFN1/R88L-expressing
cells: injection of high and lower cell numbers elicited tu-
mors, but with a considerable delay in growth. Because the
profilin mutant PFN1/Y59A is severely, and PFN1/R88L
slightly defective in actin binding (Table 1), these data again
underline the importance of an intact actin binding site in
profilin for tumor suppression. Figure 6 shows the gross
morphology and histopathology of the tumors developed in
representative animals 11 wk after injection. Mice inoculated
with 106 CAL51 parental or PFN1/Y59A-expressing cells
displayed large, well vascularized tumors at the site of in-
Figure 3. Spreading of epithelial, tumor, and profilin-reconstituted
cell lines in tissue culture. Cells were seeded on glass coverslips and
allowed to adhere for 30 min before fixation and staining with
rhodamine-phalloidin to reveal the microfilament system. (A) Flu-
orescence images to show the criteria used to divide cells into two
groups: those that have already spread and display a flat morphol-
ogy with microfilament bundles (group 1), and those that are still
compact and globular (group 2). (B) Quantitation of cells classified
in group 1. For explanation of different lines, see Figure 1. Bars
reflect the results obtained in three independent experiments, with
SEs. Note that the epithelial line MCF-10A, the profilin-reconsti-
tuted line PFN1–1 and the lines expressing profilin defective in
either PIP2 or poly-proline binding have a high proportion of cells
already well spread, whereas for CAL51, the mock-transfected cell
line and the lines expressing profilin defective in actin-binding, the
proportion of well spread cells is significantly lower (see MATERI-
ALS AND METHODS for statistical analysis).
Figure 4. Growth dependence and morphological differentiation
of CAL51 parental cells and various derivatives on matrigel. Pic-
tures were taken 6 d after seeding. For explanation of different lines,
see Figure 1. Note that the lines reconstituted with either wild-type
profilin or profilin mutants defective in PIP2- or poly-proline bind-
ing have developed flat sheets of epithelioid cells (white arrow-
heads) connected by epithelioid tubes (black arrowheads). In con-
trast, the parental tumor line CAL51, the mock-transfected CAL51
cells and the clone expressing PFN1/Y59A, the mutant severely
defective in actin-binding, display compact, undifferentiated colo-
nies. Bar, 100 m.
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jection. In contrast, injection of cells expressing the PFN1/
R88L profilin mutant resulted in much smaller lumps with
less obvious vascularization. Mice injected with PFN1/
H133S-expressing cells did not show obvious tumors (Figure
6A). Histopathological examination of tissue samples taken
from mice injected with PFN1/Y59A- or PFN1/R88L-ex-
pressing cells revealed a high density of typical tumor cells,
but tissue from the site of injection of PFN1/H133S-express-
ing cells still contained some islands of cells different in
morphology from the surrounding mouse tissue, possibly
human tumor cells (Figure 6B).
The persistence of the expression of the profilin mutant
originally introduced into the various lines was monitored
by immunoblotting: aliquots of tissue taken from the injec-
tion site were homogenized and prepared for SDS-PAGE
and quantitative immunoblotting, with standard curves for
the BiPro-tagged profilin and for purified human profilin 1,
as described in Figure 1. The results are shown in Figure 7.
All tissues of the mice depicted in Figure 6A still expressed
the transfected, exogenous profilin mutant, in addition to
the endogenous profilin, the level of which was not altered
by the transfected variant.
DISCUSSION
In a previous study, we reported tumor suppression by
elevating the PFN1 level in various human breast cancer cell
lines that display a rather low level of PFN1 mRNA and
protein compared with normal breast epithelial cells (Janke
et al., 2000). In an attempt to unravel the particular contri-
bution of binding to different ligands in the tumor suppres-
sor activity of PFN1, we used point mutants defective in
three major binding sites for ligand proteins. Our results
emphasize the particular importance of the profilin–actin
interaction for tumor suppression, especially for events re-
lated to normal cell spreading, adhesion, and differentiation
of human epithelial cells.
Mutants were chosen on the basis of a specific and selec-
tive binding defect in one ligand binding site, as seen in
biochemical and biophysical assays. As expected from our
previous work with bovine profilin 1 (Schlu¨ter et al., 1998),
the human profilin mutant PFN1/Y59A was greatly reduced
in actin binding but was not affected in binding to poly-
proline or PIP2. The mutant PFN1/R88L was normal in
poly-proline binding, showed a slight reduction in actin
binding and a substantial decrease in PIP2 binding. These
results confirm previous reports and support the notion that
arginine 88, located within the actin binding site and the
N-terminal PIP2 binding site on profilin probably contrib-
utes somewhat to actin binding, but is definitely very im-
portant for PIP2 binding (Sohn et al., 1995; Lambrechts et al.,
2002). Analysis of the third mutant, PFN1/H133S, showed
the expected failure in binding to poly-proline with well
conserved binding to actin and to PIP2. Although there is
good evidence for mutual cross talk between the binding
sites for actin, PIP2 and poly-proline stretches, extending
beyond neighboring binding sites (Lambrechts et al., 2002),
the drastic reduction in specific ligand binding by the three
mutants chosen, compiled in Table 1, seemed a good basis to
investigate the biological function of each binding site with
respect to tumor suppression. Equipping the mutants with a
tag enabled their identification in transfected cells and dis-
crimination from the endogenous protein.
To ensure that the stably transfected clones were repre-
sentative, more than one clone was generated for each mu-
tant, and two or three were used for the analyses shown. We
found that in all stable clones obtained, the expression of
endogenous profilin was unaltered, i.e., still in the range
determined for the parental CAL51 line. Remarkably, al-
though we used a promoter capable of driving a strong
expression of recombinant proteins (cytomegalovirus pro-
moter), all clones that were easy to propagate, robust for
handling, and stable in synthesizing the exogenous protein
over several months expressed the transfected profilin mu-
tant to only moderate levels, so that the overall profilin
Figure 5. Tumors obtained after injection of the different cell lines
in nude mice. For explanation of different lines, see Figure 1. (A)
Tumors obtained in relation to the number of cells injected, the
number of animals inoculated, and the size of the various tumors
obtained after 10 or 11 wk, respectively. For comparison, data
obtained from previous experiments are included (Janke et al., 2000)
and marked by an asterisk. CAL/P-25: a stable line expressing
wild-type profilin 1. (B) Development of tumors over time. The
mean tumor size and standard deviations are shown. Note that
there is not only a gross difference in the final size of tumors
obtained after 11 wk but also in the onset and velocity of tumor
growth, and no tumor resorption. Although mock-transfected
CAL51 (control) and the lines expressing profilin severely defective
in actin-binding (PFN1/Y59A) are highly tumorigenic, the lines
expressing profilin defective in PIP2 binding (PFN1/R88L) are
much less aggressive in eliciting tumors, and the lines expressing
profilin defective in poly-proline binding (PFN1/H133S) are not
capable of stimulating substantial tumor growth.
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concentration did not exceed the level found for normal
human breast epithelial cell lines. The previously deter-
mined high levels of profilin overexpression in the nontu-
morigenic CAL/17-5 line (Janke et al., 2000) were not re-
tained with time, but had also decreased to the level
indicative for breast epithelial cells, like MCF-10A. In this
context, it is noteworthy that PFN1 expression in most hu-
man tissues is within a rather narrow range, not exceeding a
threefold difference from the mean. Exceptions from this
rule are spleen and tissues with a relatively high expression
of other profilin isoforms, i.e., brain and testis (Su et al.,
2002). This indicates that human tissue differentiation, in
particular epithelial differentiation, requires a minimum
level of profilin 1. Consistent with this hypothesis is the
finding that PFN1 gene expression in gastric carcinoma is
reduced compared with normal stomach (Oien et al., 2003).
In contrast, PFN1 gene expression in different mouse tissues
is much more variable than seen for humans (Su et al., 2002),
and a 50% reduction of profilin 1 levels in heterozygous
PFN1 / animals does apparently not lead to tumor
growth (Witke et al., 2001). Hence, the role of profilin 1 as a
tumor suppressor in epithelia may be correlated with an
organism-specific tolerance against deviations from the
mean.
In standard assays generally accepted to discriminate be-
tween a transformed/tumorigenic and normal epithelial
state, we confirmed our previous findings that the elevation
of the overall profilin 1 level in human breast carcinoma cells
was capable to revert the tumorigenic state (Janke et al.,
2000). In the analysis reported here, we found prominent
differences between mutants defective in the three major
ligand binding sites, with respect to anchorage dependence,
adhesion and cell morphology, cellular organization on Ma-
trigel, and tumorigenicity in the nude mouse. The results of
these assays show that expressing PFN1 mutants with a
reduced binding capacity for PIP2 or poly-proline in CAL51
cells can lead to a reversion of several tumor cell-related
phenomena, comparable with that found for wild-type pro-
filin. In contrast, a defective actin binding site on profilin is
incompatible with a rescue to normal epithelial differentia-
tion. The finding that cells expressing the R88L mutant,
which displays a slight reduction in actin binding in addi-
tion to the defect in PIP2 binding, possess a reduced capacity
to elicit tumors, is consistent with this model.
Although our data stress the importance of the actin bind-
ing site on profilin for normal epithelial differentiation, they
do not allow for an unequivocal answer to the question of
which of the numerous profilin ligand interactions may be
involved. However, they permit a qualitative comparison of
the importance of the three major binding sites in this pro-
Figure 6. Pathology of tumors as developed
in nude mice. For explanation of different
lines, see Figure 1. (A) Gross morphology of
the animals, showing the sites of cell injection
after 11 wk (arrows). (B) Histopathology of
biopsies. Tissue looking abnormal in these
stained paraffin sections is marked by white
arrows, mouse connective tissue is indicated
by black arrows. Note that the large lumps
caused by control CAL51 cells and cells ex-
pressing the profilin mutant defective in actin-
binding (PFN1/Y59A) are heavily vascular-
ized and are primarily composed of tumor
cells (white arrows), whereas the smaller, less
well vascularized lumps generated by cells
expressing the mutant primarily defective in
PIP2-binding (PFN1/R88L) contain cells that
were histopathologically also identified as tu-
mor cells. Tissue taken from the site where
cells defective in poly-proline-binding
(PFN1/H133S) had been injected was not vas-
cularized. It contained abnormal looking cells
not unequivocally identifiable. They formed
only small islands embedded in normal
mouse tissue or fibrous material and failed to
outgrow. Bar, 50 m.
Figure 7. Expression level of endogenous and transfected profi-
lins, as seen in immunoblots obtained from tumor tissue extracts.
For explanation of different lines, see Fig. 1. Top, immunoblots
obtained with the tag antibody (BiPro antibody) or anti-profilin, to
reveal the transfected and endogenous profilin, respectively. Bot-
tom, diagram revealing the absolute amounts of endogenous profi-
lin (gray columns) and the transfected mutants (white columns),
obtained by quantitating immunoblots with antibodies against pro-
filin or the BiPro tag, respectively. The bars reflect the SD from the
mean for at least three independent analyses. Note that the tumor
tissue derived from all cell clones still express the mutated profilin
and that the level of endogenous profilin is not altered in these lines
compared with the parental CAL51.
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cess. Regarding PFN1/R88L, quantitative data on the affin-
ity of the profilin–PIP2 complex and the decrease in this
mutant are not available. The residual PIP2 binding seen for
this mutant may reflect PIP2 binding to the second binding
site which is located close to the poly-proline binding site
(Lambrechts et al., 2002; Skare and Karlsson, 2002). Appar-
ently, synthesis of this mutant protein, together with the
endogenous profilin 1, must be sufficient for epithelial dif-
ferentiation. Alternatively, reduced PIP2 binding by profilin
might be compensated by other components of the micro-
filament system that also bind to PIP2 and can act as tumor
suppressor proteins, like alpha actinin, vinculin, or gelsolin
(Vandekerckhove et al., 1990; Rodriguez Fernandez et al.,
1992; Glu¨ck et al., 1993; Asch et al., 1996; Ben Ze’ev, 1997).
Unfortunately, the significance of PIP2 binding of these pro-
teins for normal cell differentiation has not been analyzed.
PFN1/H133S was chosen because of its specific deficiency
in binding to poly-proline. In an elaborate and elegant study
with fission yeast, by using mutants with a null profilin
background, it was seen that only profilin mutants with a
residual poly-proline binding of 10% of the wild-type
value can restore viability (Lu and Pollard, 2001). Such
quantitative data cannot be expected for the system used
here, because human breast cancer cells (Janke et al., 2000) as
well as human gastric carcinoma cells (Oien et al., 2003) still
synthesize some endogenous profilin. For CAL51, we could
therefore only analyze the contribution of poly-proline bind-
ing activity for epithelial differentiation, rather than viabil-
ity. CAL51 variants expressing PFN1/H133S, which cannot
bind at all to poly-proline in vitro and thus presumably also
not to poly-proline-stretch ligands in a cellular environment,
were seen to adhere and spread at least as good as CAL51
reconstituted with wild-type profilin, developed epithelioid
structures on Matrigel and were very poor in eliciting tu-
mors. Considering the complexity of ligands interacting
with profilin via a poly-proline-stretch in mammalian cells,
this seems noteworthy. Further analysis concerning the
function of specific poly-proline-stretch ligands for profilin
in signal transduction, nuclear cytoplasmic traffic, or micro-
filament organization may unravel more subtle differences
that were not seen in our assays.
In striking contrast to the effects seen with PFN1/R88L
and PFN1/H133S were the consequences of introducing
PFN1/Y59A into CAL51 cells. The stable clones expressing
this construct had overall profilin levels well comparable
with nontumorigenic lines either reconstituted with wild-
type profilin (CAL/17-5) or expressing equivalent levels of
endogenous profilin (MCF-10A); yet, they displayed prop-
erties comparable with the parental or mock-transfected
CAL51 tumorigenic lines. A critical level of profilin with
actin binding ability for normal cell viability and prolifera-
tion was also found in the fission yeast (Lu and Pollard,
2001), and our data obtained with PFN1/Y59A in CAL51
cells illuminate the importance of profilin’s actin binding site
for cell adhesion and differentiation of human epithelial
cells.
It is tempting to speculate that it is indeed the binding of
profilin 1 to G-actin that is critical in this respect. There is a
wealth of data revealing the importance of profilin for actin
polymerization and dynamics as required for microfilament
organization of adherent and motile vertebrate cells (cf.
Schlu¨ter et al., 1997; Holt and Koffer, 2001; Pollard and
Borisy, 2003). In addition, there is recent evidence that pro-
filin–actin interaction is necessary for the export of nuclear
actin (Stu¨ven et al., 2003). However, the actin binding site on
profilin is not stringently specific for binding to actin. The
same binding site is involved in interacting with the actin-
related protein Arp2 (Machesky, 1997; Mullins et al., 1998)
which, as part of the Arp2/3 complex, is essential for the
initiation and regulation of actin polymerization in the cor-
tical region of motile cells (Pollard et al., 2001; Pollard and
Borisy, 2003). Another ligand for the same binding site is
gephyrin, a protein essential for molybdenum cofactor syn-
thesis (Stallmeyer et al., 1999; Giesemann et al., 2003). Con-
sequently, lack of a functional actin binding site in profilin
may interfere with several processes, like microfilament or-
ganization, cell adhesion, nuclear-cytoplasmic transport,
and metabolism which are all critical for epithelial differen-
tiation. Furthermore, considering that profilin is not the only
actin binding protein classified as a tumor suppressor pro-
tein (see above), it is conceivable that profilin has to act in
concert with other microfilament proteins in epithelial dif-
ferentiation. Hence, although we demonstrate that the actin
binding site in profilin 1 plays an important role in human
epithelial differentiation, further studies will be needed to
provide an explanation for this phenomenon on a molecular
level.
ACKNOWLEDGMENTS
We thank Renate Frege (MDC Berlin-Buch), Eva Saxinger, Nicola Brandt, and
Kathrin Schloen (Technical University of Braunschweig) for expert technical
help and Dr. S. Seitz (Max-Delbru¨ck-Center, Berlin-Buch) for help with pho-
tographic art work. Horst Hinssen (University of Bielefeld) is gratefully
acknowledged for a gift of pig plasma gelsolin, and Wolfgang Ziegler (Tech-
nical University of Braunschweig) for helpful discussions concerning statis-
tical data evaluation. This work was financially supported by the Deutsche
Krebshilfe/Mildred Scheel Stiftung (10-2048-Ja1) and the Fonds der Chemis-
chen Industrie (to B.M.J.).
REFERENCES
Aderem, A. (1992). Signal transduction and the actin cytoskeleton: the roles of
MARCKS and profilin. Trends Biochem. Sci. 17, 438–443.
Asch, H.L., Head, K., Dong, Y., Natoli, F., Winston, J.S., Connolly, J.L., and
Asch, B.B. (1996). Widespread loss of gelsolin in breast cancers of humans,
mice, and rats. Cancer Res. 56, 4841–4845.
Ben Ze’ev, A. (1997). Cytoskeletal and adhesion proteins as tumor suppres-
sors. Curr. Opin. Cell Biol. 9, 99–108.
Bjorkegren, C., Rozycki, M., Schutt, C.E., Lindberg, U., and Karlsson, R.
(1993). Mutagenesis of human profilin locates its poly(L-proline)-binding site
to a hydrophobic patch of aromatic amino acids. FEBS Lett. 333, 123–126.
Bjorkegren-Sjogren, C., Korenbaum, E., Nordberg, P., Lindberg, U., and Karls-
son, R. (1997). Isolation and characterization of two mutants of human profilin
I that do not bind poly(L-proline). FEBS Lett. 418, 258–64.
Buss, F., Temm-Grove, C., Henning, S., and Jockusch, B.M. (1992). Distribu-
tion of profilin in fibroblasts correlates with the presence of highly dynamic
actin filaments. Cell Motil. Cytoskeleton 22, 51–61.
Carlsson, L., Nystro¨m, N.E., Sundkvist, I., Markey, F., and Lindberg, U.
(1977). Actin polymerizability is influenced by profilin, a low molecular
weight protein in non-muscle cells. J. Mol. Biol. 115, 465–483.
Dong, J., Radau, B., Otto, A., Muller, E., Lindschau, C., and Westermann, P.
(2000). Profilin I attached to the Golgi is required for the formation of
constitutive transport vesicles at the trans-Golgi network. Biochim. Biophys.
Acta 1497, 253–260.
Giesemann, T., Rathke-Hartlieb, S., Rothkegel, M., Bartsch, J.W., Buchmeier,
S., Jockusch, B.M., and Jockusch, H. (1999). A role for polyproline motifs in the
spinal muscular atrophy protein SMN: profilins bind to and colocalize with
SMN in nuclear gems. J. Biol. Chem. 274, 37908–37914.
Giesemann, T., Schwarz, G., Nawrotzki, R., Berho¨rster, K., Rothkegel, M.,
Schlu¨ter, K., Schrader, N., Schindelin, H., Mendel, R.R., and Jockusch, B.M.
(2003). Complex formation between the postsynaptic scaffolding protein
gephyrin, profilin and Mena: a possible link to the microfilament system.
J. Neurosci. 23, 8330–8339.
Glu¨ck, U., Kwiatkowski, D.J., and Ben-Ze’ev, A. (1993). Suppression of tu-
morigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-
actinin cDNA. Proc. Natl. Acad. Sci. USA 90, 383–387.
Tumor Suppression by Profilin 1
Vol. 15, April 2004 1607
Goldschmidt-Clermont, P.J., Furman, M.I., Wachsstock, D., Safer, D., Nach-
mias, V.T., and Pollard, T.D. (1992). The control of actin nucleotide exchange
by thymosin beta 4 and profilin. A potential regulatory mechanism for actin
polymerization in cells. Mol. Biol. Cell 3, 1015–1024.
Goldschmidt-Clermont, P.J., Machesky, L.M., Baldassare, J.J., and Pollard,
T.D. (1990). The actin-binding protein profilin binds to PIP2 and inhibits its
hydrolysis by phospholipase C. Science 247, 1575–1578.
Haugwitz, M., Noegel, A.A., Karakesisoglou, J., and Schleicher, M. (1994).
Dictyostelium amoebae that lack G-actin-sequestering profilins show defects
in F-actin content, cytokinesis, and development. Cell 79, 303–314.
Holt, M.R., and Koffer, A. (2001). Cell motility: proline-rich proteins promote
protrusions. Trends Cell Biol. 11, 38–46.
Hu¨ttelmaier, S., Mayboroda, O., Harbeck, B., Jarchau, T., Jockusch, B.M., and
Ru¨diger, M. (1998). The interaction of the cell-contact proteins VASP and
vinculin is regulated by phosphatidylinositol-4,5-bisphosphate. Curr. Biol. 8,
479–488.
Janke, J., Schluter, K., Jandrig, B., Theile, M., Kolble, K., Arnold, W., Grinstein,
E., Schwartz, A., Estevez-Schwarz, L., Schlag, P. M. et al. (2000). Suppression
of tumorigenicity in breast cancer cells by the microfilament protein profilin
1. J. Exp. Med. 191, 1675–86.
Krebs, A., Rothkegel, M., Klar, M., and Jockusch, B.M. (2001). Characteriza-
tion of functional domains of mDia1, a link between the small GTPase Rho
and the actin cytoskeleton. J. Cell Sci. 114, 3663–3672.
Lambrechts, A., Jonckheere, V., Dewitte, D., Vandekerckhove, J., and Ampe,
C. (2002). Mutational analysis of human profilin I reveals a second PIP2
binding site neighbouring the poly(L-proline)binding site. BMC Biochem. 3,
12.
Lambrechts, A., Verschelde, J.L., Jonckheere, V., Goethals, M., Vandekerck-
hove, J., and Ampe, C. (1997). The mammalian profilin isoforms display
complementary affinities for PIP2 and proline-rich sequences. EMBO J. 16,
484–494.
Lassing,I.,andLindberg,U.(1985).Specificinteractionbetweenphosphatidylino-
sitol 4,5-bisphosphate and profilactin. Nature 314, 472–474.
Lindberg, U., Schutt, C.E., Hellsten, E., Tjader, A.C., and Hult, T. (1988). The
use of poly(L-proline)-Sepharose in the isolation of profilin and profilactin
complexes. Biochim. Biophys. Acta 967, 391–400.
Lu, J., and Pollard, T.D. (2001). Profilin binding to poly-L-proline and actin
monomers along with ability to catalyze actin nucleotide exchange is required
for viability of fission yeast. Mol. Biol. Cell 12, 1161–75.
Machesky, L.M. (1997). Cell motility: complex dynamics at the leading edge.
Curr. Biol. 7, R164–R167.
Machesky, L.M., and Pollard, P.D. (1993). Profilin as a potential mediator of
membrane-cytoskeleton communication. Trends Cell Biol. 3, 381–385.
Magdolen, V., Oechsner, U., Muller, G., and Bandlow, W. (1988). The intron-
containing gene for yeast profilin (PFY) encodes a vital function. Mol. Cell.
Biol. 8, 5108–5115.
Mayboroda, O., Schlu¨ter, K., and Jockusch, B.M. (1997). Differential colocal-
ization of profilin with microfilaments in PtK2 cells. Cell Motil. Cytoskeleton
37, 166–177.
Mullins, R.D., Heuser, J.A., and Pollard, T.D. (1998). The interaction of Arp2/3
complex with actin: nucleation, high affinity pointed end capping, and for-
mation of branching networks of filaments. Proc. Natl. Acad. Sci. USA 95,
6181–6186.
Oien, K.A., Vass, J.K., Downie, I., Fullarton, G., and Keith, W.N. (2003).
Profiling, comparison and validation of gene expression in gastric carcinoma
and normal stomach. Oncogene 22, 4287–4300.
Pantaloni, D., and Carlier, M.F. (1993). How profilin promotes actin filament
assembly in the presence of thymosin beta 4. Cell 75, 1007–1014.
Perelroizen, I., Didry, D., Christensen, H., Chua, N.H., and Carlier, M.F.
(1996). Role of nucleotide exchange and hydrolysis in the function of profilin
in actin assembly. J. Biol. Chem. 271, 12302–12309.
Petersen, O.W., Ronnov-Jessen, L., Howlett, A.R., and Bissell, M.J. (1992).
Interaction with basement membrane serves to rapidly distinguish growth
and differentiation pattern of normal and malignant human breast epithelial
cells. Proc. Natl. Acad. Sci. USA 89, 9064–9068.
Pollard, T.D., Blanchoin, L., and Mullins, R.D. (2001). Actin dynamics. J. Cell
Sci. 114, 3–4.
Pollard, T.D., and Borisy, G.G. (2003). Cellular motility driven by assembly
and disassembly of actin filaments. Cell 113, 549
Reinhard, M., Giehl, K., Abel, K., Haffner, C., Jarchau, T., Hoppe, V., Jockusch,
B.M., and Walter, U. (1995). The proline-rich focal adhesion and microfila-
ment protein VASP is a ligand for profilins. EMBO J. 14, 1583–1589.
Rodriguez Fernandez, J.L., Geiger, B., Salomon, D., Sabanay, I., Zoller, M. and
Ben-Ze’ev, A. (1992). Suppression of tumorigenicity in transformed cells after
transfection with vinculin cDNA. J. Cell Biol. 119, 427–438.
Ru¨diger, M., Jockusch, B.M., and Rothkegel, M. (1997). An epitope tag-
antibody combination useful for the detection of protein expression in pro-
caryotic and eukaryotic cells. Biotechniques 23, 96–97.
Scha¨gger, H., and Jagow, G.V. (1987). Tricine sodium dodecylsulfate poly-
acrylamide gel electrophoresis for the separation of proteins in the range from
1–100 kDa. Anal. Biochem. 166, 368–379.
Schlu¨ter, K., Jockusch, B.M., and Rothkegel, M. (1997). Profilins as regulators
of actin dynamics. Biochim. Biophys. Acta 27, 97–109.
Schlu¨ter, K., Schleicher, M., and Jockusch, B.M. (1998). Effects of single amino
acid substitutions in the actin-binding site on the biological activity of bovine
profilin I. J. Cell Sci. 111, 3261–3273.
Skare, P., and Karlsson, R. (2002). Evidence for two interaction regions for
phosphatidylinositol (4,5)-bisphosphate on mammalian profilin I. FEBS Lett.
522, 119–124.
Skare, P., Kreivi, J.P., Bergstrom, A., and Karlsson, R. (2003). Profilin I colo-
calizes with speckles and Cajal bodies: a possible role in pre-mRNA splicing.
Exp. Cell Res. 286, 12–21.
Sohn, R.H., Chen, J., Koblan, K.S., Bray, P.F., and Goldschmidtclermont, P.J.
(1995). Localization of a binding site for phosphatidylinositol 4,5-bisphos-
phate on human profilin. J. Biol. Chem. 270, 21114–21120.
Stallmeyer, B., Schwarz, G., Schulze, J., Nerlich, A., Reiss, J., Kirsch, J., and
Mendel, R.R. (1999). The neurotransmitter receptor-anchoring protein gephy-
rin reconstitutes molybdenum cofactor biosynthesis in bacteria, plants, and
mammalian cells. Proc. Natl. Acad. Sci. USA 96, 1333–1338.
Stu¨ven, T., Hartmann, E., and Go¨rlich, D. (2003). Exportin 6, a novel nuclear
export receptor that is specific for profilin-actin complexes. EMBO J. 22,
5928–5940.
Su, A.I., et al. (2002). Large-scale analysis of the human and mouse transcrip-
tomes. Proc. Natl. Acad. Sci. USA 99, 4465–4470.
Suetsugu, S., Miki, H., and Takenawa, T. (1998). The essential role of profilin
in the assembly of actin for microspike formation. EMBO J. 17, 6516–26.
Tanaka, M., and Shibata, H. (1985). Poly(L-proline)-binding proteins from
chick embryos are a profilin and a profilactin. Eur. J. Biochem. 151, 291–297.
Theile, M., Hartmann, S., Scherthan, H., Arnold, W., Deppert, W., Frege, R.,
Glaab, F., Haensch, W., and Scherneck, S. (1995). Suppression of tumorige-
nicity of breast cancer cells by transfer of human chromosome 17 does not
require transferred BRCA1 and p53 genes. Oncogene 10, 439–447.
Vandekerckhove, J., Bauw, G., Vancampernolle, K., Honore, B., and Celis, J.
(1990). Comparative two-dimensional gel analysis and microsequencing iden-
tifies gelsolin as one of the most prominent downregulated markers of trans-
formed human fibroblast and epithelial cells. J. Cell Biol. 111, 95–102.
Verheyen, E.M., and Cooley, L. (1994). Profilin mutations disrupt multiple
actin-dependent processes during Drosophila development. Development 120,
717–728.
Watanabe, N., Madaule, P., Reid, T., Ishizaki, T., Watanabe, G., Kakizuka, A.,
Saito, Y., Nakao, K., Jockusch, B.M., and Narumiya, S. (1997). p140mDia, a
mammalian homologue of Drosophila diaphanous, is a target protein for rho
small GTPases and is a ligand for profilin. EMBO J. 16, 3044–3056.
Witke, W., Sharpe, A.H., and Kwiatkowski, D.J. (1993). Profilin deficient mice
are not viable. Mol. Biol. Cell 4, 149a.
Witke, W., Sutherland, J.D., Sharpe, A., Arai, M., and Kwiatkowski, D.J.
(2001). Profilin I is essential for cell survival and cell division in early mouse
development. Proc. Natl. Acad. Sci. USA 98, 3832–3836.
Wittenmayer, N., Rothkegel, M., Jockusch, B.M., and Schlu¨ter, K. (2000).
Functional characterization of green fluorescent protein-profilin fusion pro-
teins. Eur. J. Biochem. 267, 5247–5256.
N. Wittenmayer et al.
Molecular Biology of the Cell1608
